Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
Podcast: Play in new window | Download
Subscribe: Google Podcasts | Spotify | Stitcher | Blubrry | JioSaavn | TuneIn | RSS | MoreCLICK HERE to participate in our episode survey.
Mentioned on this episode:
- Mantle Cell Lymphoma
- Mantle Cell Lymphoma (MCL) with Dr. Benjamin Lampson: What Patients Should Know episode
- CAR T cell Therapy
- Highlights from ASH conference
Additional LLS Support Resources:
- Information Specialists
- Financial support
- Free telephone/web patient programs
- Patti Robinson Kaufmann First Connection Program
- Free booklets
- LLS Public Policy & Advocacy
- Clinical Trial Support Center
- Online chats
- Caregiver support
- LLS Community
- Support groups
- Free Nutrition Consultations
- LLS Advocacy
- Survivorship Workbook
Support for this episode provided by Bristol Myers Squibb; CRISPR Therapeutics; Janssen Oncology & Legend Biotech; KITE, a Gilead Company and Novartis Pharmaceuticals Corporation.
This episode was very informative. The fact that there is ‘No free Lunch’ as was mentioned is glossed over by many if not most of the articles and news sources when it comes to new treatments that are very effective. It makes me reconsider if I would want CAR-T at this time since the current regimen of Zanubrutinib is apparently working without many side issues.
I too thank you for the information. CAR-T Cell therapy will definitely be a direction I’ll look at with my UCSF doctor if Zanabrutinib’s effectiveness wanes or becomes toxic. It’s been terrific for a year. I question it’s cost. I am generally excited about the progress of treatments for MCL. Tomorrow will only be better, though today has been mighty fine.